copanlisib dihydrochloride · Bayer Healthcare · NDA 209936
Aliqopa
Earliest generic entry, as listed
29 Mar 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10383876, US 9636344.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10383876 | substance, product | 29 Mar 2032 |
| US 9636344 | use U-2124 | 29 Mar 2032 |
| US RE46856 | substance, product, use U-2124 | 22 Oct 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209936 · 001 · RLD · discontinued | powder, intravenous | 60MG/VIAL | 29 Mar 2032 |